Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases
Since its discovery in 1984 by Svetlana Mosjov, GLP-1 and its analogs (such as semaglutide, liraglutide, and dulaglutide) have rapidly become cornerstone treatments for type 2 diabetes mellitus (T2DM) and obesity
It won't have the same degree of weight loss from what we can see in the early trials, she advises, but it will help retain lean muscle mass, which we inevitably lose over our lifetime. Given that semaglutide is a lifelong drug, the long-term data on GLP-1 agonists is reassuringly positive
Ung lc no? , bn hy da vo thnh phn a ra quyt nh
Yes, our formulas are non-comedogenic, meaning they are designed not to clog pores